Seek immediate medical attention if you experience chest pain, difficulty swallowing, persistent vomiting, or signs of gastrointestinal bleeding alongside reflux
TRIUMPH-1 (NCT05929066), the Phase 3 registration trial for the obesity indication, reported topline results on May 21, 2026 : average weight loss of 28.3% at 80 weeks at the highest dose in 2,339 participants, versus 2.2% on placebo, and 30.3% at 104 weeks among participants with a BMI of 35 or above who continued in a pre-specified extension
Extending treatment duration or shortening the time horizon increased the ICER (up to 17,643)
The volunteers, along with city workers, will have to haul them out on sleds